Trial reportJournal of substance abuse treatment2015
Buprenorphine pharmacotherapy and behavioral treatment: comparison of outcomes among prescription opioid users, heroin users and combination users.
Trial report in Journal of substance abuse treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Opioid agonist treatment for people who are dependent on pharmaceutical opioids.The Cochrane database of systematic reviews · 2022Pooled it
- Treatment-seeking behaviour among people with opioid use disorder in the high-income countries: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Characterizing opioid withdrawal during double-blind buprenorphine detoxification.Drug and alcohol dependence · 2015Trial
- Dosage and Administration-Related Emotional and Clinical Outcomes of Buprenorphine Treatment for Opioid Use Disorder: A Systematic Review and Meta-Analysis.Healthcare (Basel, Switzerland) · 2026Review
- Pharmacological Strategies to Decrease Long-Term Prescription Opioid Use: A Systematic Review.Journal of clinical medicine · 2024Review
- Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.Drug and alcohol dependence reports · 2024Article
- Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings.Journal of substance abuse treatment · 2021Article
- The "black box" of treatment: Patients' perspective on what works in opioid maintenance treatment for opioid dependence.Substance abuse treatment, prevention, and policy · 2021Article
- Buprenorphine Treatment for Opioid Use Disorder in Community-Based Settings: Outcome Related to Intensity of Services and Urine Drug Test Results.The American journal on addictions · 2020Article
- A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse.Journal of medicinal chemistry · 2018Article
- Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.The American journal on addictions · 2017Article
- Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample.Drug and alcohol dependence · 2017Article
- Estimating State Transitions for Opioid Use Disorders.Medical decision making : an international journal of the Society for Medical Decision Making · 2017Article
- Perceived risk of heroin use among nonmedical prescription opioid users.Addictive behaviors · 2017Article
- Delay discounting in opioid use disorder: Differences between heroin and prescription opioid users.Drug and alcohol dependence · 2016Article
- Prescription drug abuse: from epidemiology to public policy.Journal of substance abuse treatment · 2015Review
- Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.Journal of addiction medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Most research examining buprenorphine has been conducted with heroin users. Few studies have examined buprenorphine pharmacotherapy for prescription opioid users. Data were from a randomized controlled trial of behavioral treatment provided for 16weeks on a platform of buprenorphine pharmacotherapy and medication management. We compared heroin (H, n=54), prescription opioid (PO, n=54) and combination heroin+prescription opioid (POH, n=71) users to test the hypothesis that PO users will have better treatment outcomes compared with heroin users. The PO group provided more opioid-negative urine drug screens over the combined treatment period (PO:70%, POH:40%, H:38%, p<0.001) and at the end of the combined treatment period (PO:65%, POH:31%, H:33%, p<0.001). Retention was lowest in the H group (PO:80%, POH:65%, H:57%, p=0.039). There was no significant difference in buprenorphine dose between the groups. PO users appear to have better outcomes in buprenorphine pharmacotherapy compared to those reporting any heroin use, confirming that buprenorphine pharmacotherapy is effective in PO users.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.